Registered title, quoted from ClinicalTrials.gov
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06561178, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 2
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (2 points)Hide the checklist
Have received neoadjuvant chemoradiotherapy ± immunotherapy and have not achieved pCR after R0 resection;
Inclusion criterion 2
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
Inclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06561178, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Operable locally advanced esophageal squamous cell carcinoma;
- Have received neoadjuvant chemoradiotherapy ± immunotherapy and have not achieved pCR after R0 resection;
- Can tolerate postoperative adjuvant immunotherapy;
- Sufficient baseline tumor tissue and blood samples available for NGS testing;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- Consents to and is capable of complying with the scheduled study visits, treatment plans, laboratory tests, and other study procedures
- Expected postoperative survival time of ≥ 6 months.
Exclusion Criteria:
- Concurrent other malignant tumors;
- Lack of a detailed histopathological diagnostic report for determining the nature of the lesion;
- Severe and/or poorly controlled medical conditions that, in the investigator's judgment, could affect participation or interfere with study results;
- Any social/psychological issues that, in the investigator's judgment, make the patient unsuitable for participation;
- Unable to undergo long-term, regular postoperative follow-up at the current medical institution;
- Unwilling or unable to comply with the study protocol.
Quoted from ClinicalTrials.gov, NCT06561178, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06561178, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.